Clinical Study of UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This is a single-arm, open-label, dose-escalation study to explore the safety, efficacy, and cytodynamic characteristics of the drug, and to initially observe the efficacy of the drug in subjects with relapsed/refractory B7-H3-positive acute myeloid cell line leukemia.
Relapsed/Refractory Acute Myeloid Leukemia
BIOLOGICAL: gdT cell injection targeting B7-H3 chimeric antigen receptor
Assessment of the safety after UTAA06 injection treatment (Safety), Number of participants with treatment-related adverse events as assessed by CTCAE v5.0., About 2 years
To evaluate anti-tumor activity (overall survival), Defined as the time from start of UTAA06 UTAA06 infusion therapy to death (due to any cause), About 2 years|To evaluate anti-tumor activity (duration of response), Defined as the time from the first tumor assessment of CR or PR, CR or CRi to the first assessment of disease recurrence or progression or death (due to any cause)., About 2 years|To evaluate anti-tumor activity (progression free survival), Defined as the time from the start of UTAA06 infusion therapy to the first disease progression or recurrence or death from any cause., About 2 years
Eligible subjects will receive 1.0×10\^8 CAR gdT, 2.0×10\^8 CAR gdT, 4.0×10\^8 CAR gdT, or additional doses may be added at the discretion of investigator and sponsor.